nach oben

Heart Failure Reviews

Erschienen in:

17.02.2018

Percutaneous left atrial appendage occlusion in the prevention of stroke in atrial fibrillation: a systematic review

verfasst von: Jayson R. Baman, Moussa Mansour, E. Kevin Heist, David T. Huang, Yitschak Biton

Erschienen in: Heart Failure Reviews | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Atrial fibrillation is commonly coexistent with heart failure, and the management of the heart failure patient would be incomplete without an appreciation for atrial fibrillation management. There are many complications associated with oral anticoagulation in the prevention of stroke related to atrial fibrillation. In recent years, the advent of several percutaneous left atrial appendage (LAA) occlusion/closure strategies has sought to provide an alternative treatment modality. Here, we systematically review the published literature to investigate the efficacy and safety of percutaneous LAA occlusion/closure devices. We searched PubMed, EMBASE, Cochrane database of systematic reviews, and the FDA Medical Devices database. Using prespecified criteria, we identified studies of the Amplatzer Cardiac Plug (St. Jude Medical), Amplatzer Amulet (St. Jude Medical), Lariat suture delivery device (SentreHeart), and Watchman device (Boston Scientific). We analyzed 2 randomized controlled trials (RCT) and 15 non-randomized registries that satisfied the study criteria. The two RCT both studied the Watchman device versus standard warfarin therapy; the studies indicate that the Watchman may be non-inferior to warfarin. Long-term efficacy outcomes for the Watchman device are promising. Data regarding the Amplatzer Cardiac Plug, Amplatzer Amulet, and Lariat suture delivery device are limited by the paucity of RCT data. High-quality prospective research is needed to directly compare LAA occlusion/closure strategies against one another as well as versus the direct oral anticoagulation medications. Data regarding the role of LAA occlusion in the heart failure population are lacking.

Nur mit Berechtigung zugänglich

Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X (2013) Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 112(8):1142–1147. https://doi.org/10.1016/j.amjcard.2013.05.063 CrossRefPubMed

Sartipy U, Dahlström U, Fu M, Lund LH (2017) Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 5(8):565–574. https://doi.org/10.1016/j.jchf.2017.05.001 CrossRefPubMed

Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Ballman KV, Meverden RA, Roger VL (2006) Ischemic stroke after heart failure: a community-based study. Am Heart J 152(1):102–109. https://doi.org/10.1016/j.ahj.2005.10.018 CrossRefPubMed

Lubitz SA, Benjamin EJ, Ellinor PT (2010) Atrial fibrillation in congestive heart failure. Heart Fail Clin 6(2):187–200. https://doi.org/10.1016/j.hfc.2009.11.001 CrossRefPubMedPubMedCentral

Wolf PA, Dawber TR, Thomas HE, Kannel WB (1978) Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 28(10):973–977. https://doi.org/10.1212/WNL.28.10.973 CrossRefPubMed

Petty GW, Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO (2000) Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence. Stroke 31(5):1062–1068. https://doi.org/10.1161/01.STR.31.5.1062 CrossRefPubMed

Saw J, Lempereur M (2014) Percutaneous left atrial appendage closure: procedural techniques and outcomes. JACC Cardiovasc Interv 7(11):1205–1220. https://doi.org/10.1016/j.jcin.2014.05.026 CrossRefPubMed

Baker WL, Cios DA, Sander SD, Coleman CI (2009) Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 15(3):244–252. https://doi.org/10.18553/jmcp.2009.15.3.244 PubMed

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151. https://doi.org/10.1056/NEJMoa0905561 CrossRefPubMed

10.

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM, the ROCKET AF Steering Committee (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891. https://doi.org/10.1056/NEJMoa1009638 CrossRefPubMed

11.

Granger CB, Alexander JH, McMurray J, Lopes RD, Hylek EM, Hanna M, al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992. https://doi.org/10.1056/NEJMoa1107039 CrossRefPubMed

12.

Boos CJ, Nam M, Camm AJ (2014) Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart Fail Rev 19(3):391–401. https://doi.org/10.1007/s10741-013-9398-3 CrossRefPubMed

13.

Visser LE, Bleumink GS, Trienekens PH, Vulto AG, Hofman A, Stricker BHC (2004) The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol 127(1):85–89. https://doi.org/10.1111/j.1365-2141.2004.05162.x CrossRefPubMed

14.

Blackshear JL, Odell JA (1996) Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 61(2):755–759. https://doi.org/10.1016/0003-4975(95)00887-X CrossRefPubMed

15.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100. https://doi.org/10.1371/journal.pmed.1000100 CrossRefPubMedPubMedCentral

16.

Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P (2009) Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374(9689):534–542. https://doi.org/10.1016/S0140-6736(09)61343-X CrossRefPubMed

17.

Holmes DR Jr et al (2014) Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 64(1):1–12. https://doi.org/10.1016/j.jacc.2014.04.029 CrossRefPubMed

18.

Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S (2011) Safety of percutaneous left atrial appendage closure: results from the watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the continued access registry. Circulation 123(4):417–424. https://doi.org/10.1161/CIRCULATIONAHA.110.976449 CrossRefPubMed

19.

Reddy VY, Möbius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, Sick P, Sievert H (2013) Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix feasibility study with watchman left atrial appendage closure technology). J Am Coll Cardiol 61(25):2551–2556. https://doi.org/10.1016/j.jacc.2013.03.035 CrossRefPubMed

20.

Reddy VY, Gibson DN, Kar S, O’Neill W, Doshi SK, Horton RP, Buchbinder M, Gordon NT, Holmes DR (2017) Post-approval U.S. experience with left atrial appendage closure for stroke prevention in atrial fibrillation. J Am Coll Cardiol 69(3):253–261. https://doi.org/10.1016/j.jacc.2016.10.010 CrossRefPubMed

21.

Holmes DR Jr, Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H, Valderrabano M, Reddy VY (2015) Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 65(24):2614–2623. https://doi.org/10.1016/j.jacc.2015.04.025 CrossRefPubMed

22.

Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, Pokushalov E, Kische S, Schmitz T, Stein KM, Bergmann MW, EWOLUTION investigators (2016) Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 37(31):2465–2474. https://doi.org/10.1093/eurheartj/ehv730 CrossRefPubMedPubMedCentral

23.

Bartus K, Han FT, Bednarek J, Myc J, Kapelak B, Sadowski J, Lelakowski J, Bartus S, Yakubov SJ, Lee RJ (2013) Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol 62(2):108–118. https://doi.org/10.1016/j.jacc.2012.06.046 CrossRefPubMed

24.

Price MJ, Gibson DN, Yakubov SJ, Schultz JC, di Biase L, Natale A, Burkhardt JD, Pershad A, Byrne TJ, Gidney B, Aragon JR, Goldstein J, Moulton K, Patel T, Knight B, Lin AC, Valderrábano M (2014) Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. J Am Coll Cardiol 64(6):565–572. https://doi.org/10.1016/j.jacc.2014.03.057 CrossRefPubMedPubMedCentral

25.

Lakkireddy D, Afzal MR, Lee RJ, Nagaraj H, Tschopp D, Gidney B, Ellis C, Altman E, Lee B, Kar S, Bhadwar N, Sanchez M, Gadiyaram V, Evonich R, Rasekh A, Cheng J, Cuoco F, Chandhok S, Gunda S, Reddy M, Atkins D, Bommana S, Cuculich P, Gibson D, Nath J, Ferrell R, Matthew E, David Wilb║║"affiliation provided but citation not provided.so i given for last author... -->er (2016) Short and long-term outcomes of percutaneous left atrial appendage suture ligation: results from a US multicenter evaluation. Heart Rhythm 13(5):1030–1036. https://doi.org/10.1016/j.hrthm.2016.01.022 CrossRefPubMed

26.

Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G, Kefer J, Landmesser U, Nielsen-Kudsk JE, Cruz-Gonzalez I, Sievert H, Tichelbäcker T, Kanagaratnam P, Nietlispach F, Aminian A, Kasch F, Freixa X, Danna P, Rezzaghi M, Vermeersch P, Stock F, Stolcova M, Costa M, Ibrahim R, Schillinger W, Meier B, Park JW (2016) Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention 11(10):1170–1179. https://doi.org/10.4244/EIJY15M01_06 CrossRefPubMed

27.

Mínguez JR et al (2015) Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure. Heart 101(11):877–883. https://doi.org/10.1136/heartjnl-2014-306332 CrossRef

28.

Urena M, Rodés-Cabau J, Freixa X, Saw J, Webb JG, Freeman M, Horlick E, Osten M, Chan A, Marquis JF, Champagne J, Ibrahim R (2013) Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol 62(2):96–102. https://doi.org/10.1016/j.jacc.2013.02.089 CrossRefPubMed

29.

Kleinecke C, Park JW, Gödde M, Zintl K, Schnupp S, Brachmann J (2017) Twelve-month follow-up of left atrial appendage occlusion with Amplatzer Amulet. Cardiol J 24(2):131–138. https://doi.org/10.5603/CJ.a2017.0017 CrossRefPubMed

30.

Koskinas KC, Shakir S, Fankhauser M, Nietlispach F, Attinger-Toller A, Moschovitis A, Wenaweser P, Pilgrim T, Stortecky S, Praz F, Räber L, Windecker S, Meier B, Gloekler S (2016) Predictors of early (1-week) outcomes following left atrial appendage closure with Amplatzer devices. JACC Cardiovasc Interv 9(13):1374–1383. https://doi.org/10.1016/j.jcin.2016.04.019 CrossRefPubMed

31.

Berti S, Pastormerlo LE, Rezzaghi M, Trianni G, Paradossi U, Cerone E, Ravani M, de Caterina AR, Rizza A, Palmieri C (2016) Left atrial appendage occlusion in high-risk patients with non-valvular atrial fibrillation. Heart 102(24):1969–1973. https://doi.org/10.1136/heartjnl-2015-309150 CrossRefPubMed

32.

Kim JS, Lee H, Suh Y, Pak HN, Hong GR, Shim CY, Yu CW, Lee HJ, Kang WC, Shin ES, Choi RK, Kar S, Park JW, Lim DS, Jang Y (2016) Left atrial appendage occlusion in non-valvular atrial fibrillation in a Korean multi-center registry. Circ J 80(5):1123–1130. https://doi.org/10.1253/circj.CJ-15-1134 CrossRefPubMed

33.

Masoudi FA, Calkins H, Kavinsky CJ, Drozda JP Jr, Gainsley P, Slotwiner DJ, Turi ZG (2015) 2015 ACC/HRS/SCAI left atrial appendage occlusion device societal overview. J Am Coll Cardiol 66(13):1497–1513. https://doi.org/10.1016/j.jacc.2015.06.028 CrossRefPubMed

34.

Reddy VY et al (2016) Post-FDA approval, initial US clinical experience with watchman left atrial appendage closure for stroke prevention in atrial fibrillation. J Am Coll Cardiol

35.

Price MJ, Reddy VY, Valderrábano M, Halperin JL, Gibson DN, Gordon N, Huber KC, Holmes DR Jr (2015) Bleeding outcomes after left atrial appendage closure compared with long-term warfarin: a pooled, patient-level analysis of the WATCHMAN randomized trial experience. JACC Cardiovasc Interv 8(15):1925–1932. https://doi.org/10.1016/j.jcin.2015.08.035 CrossRefPubMed

36.

Lackland DT, Elkind MS, D'Agostino R Sr, Dhamoon MS, Goff DC Jr, Higashida RT, McClure L, Mitchell PH, Sacco RL, Sila CA, Smith SC Jr, Tanne D, Tirschwell DL, Touzé E, Wechsler LR, American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Quality of Care and Outcomes Research (2012) Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 43(7):1998–2027. https://doi.org/10.1161/STR.0b013e31825bcdac CrossRefPubMed

37.

Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, Horton RP, Buchbinder M, Neuzil P, Gordon NT, Holmes DR Jr, PREVAIL and PROTECT AF Investigators (2017) 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 70(24):2964–2975. https://doi.org/10.1016/j.jacc.2017.10.021 CrossRefPubMed

38.

Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G, Kefer J, Landmesser U, Nielsen-Kudsk JE, Cruz-Gonzalez I, Sievert H, Tichelbäcker T, Kanagaratnam P, Nietlispach F, Aminian A, Kasch F, Freixa X, Danna P, Rezzaghi M, Vermeersch P, Stock F, Stolcova M, Costa M, Ibrahim R, Schillinger W, Meier B, Park JW (2016) Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER cardiac plug. EuroIntervention 11(10):1170–1179. https://doi.org/10.4244/EIJY15M01_06 CrossRefPubMed

39.

Holmes DR et al (2015) Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 65(24):2614–2623. https://doi.org/10.1016/j.jacc.2015.04.025 CrossRefPubMed

40.

Lip GY, Halperin JL (2010) Improving stroke risk stratification in atrial fibrillation. Am J Med 123(6):484–488. https://doi.org/10.1016/j.amjmed.2009.12.013 CrossRefPubMed

41.

Tung MK et al (2016) Retrospective cohort study examining reduced intensity and duration of anticoagulant and antiplatelet therapy following left atrial appendage occlusion with the WATCHMAN device. Heart Lung Circ

42.

Enomoto Y, Gadiyaram VK, Gianni C, Horton RP, Trivedi C, Mohanty S, di Biase L, al-Ahmad A, Burkhardt JD, Narula A, Janczyk G, Price MJ, Afzal MR, Atoui M, Earnest M, Swarup V, Doshi SK, van der Zee S, Fisher R, Lakkireddy DR, Gibson DN, Natale A, Reddy VY (2017) Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device. Heart Rhythm 14(1):19–24. https://doi.org/10.1016/j.hrthm.2016.10.020 CrossRefPubMed

43.

Holmes DR, Reddy VY, Buchbinder M, Stein K, Elletson M, Bergmann MW, Schmidt B, Saw J (2017) The assessment of the Watchman device in patients unsuitable for oral anticoagulation (ASAP-TOO) trial. Am Heart J 189:68–74. https://doi.org/10.1016/j.ahj.2017.03.007 CrossRefPubMed

44.

Bergmann MW et al (2017) Early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: safety and efficacy. EuroIntervention 13(7):877–884. https://doi.org/10.4244/EIJ-D-17-00042 CrossRefPubMed

45.

January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64(21):e1–76. https://doi.org/10.1016/j.jacc.2014.03.022 CrossRefPubMed

46.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, de Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GYH, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962. https://doi.org/10.1093/eurheartj/ehw210 CrossRefPubMed

47.

Seeger J, Birkemeyer R, Rottbauer W, Wöhrle J (2017) First experience with the Watchman FLX occluder for percutaneous left atrial appendage closure. Cardiovasc Revasc Med 18(7):512–516. https://doi.org/10.1016/j.carrev.2017.04.018 CrossRefPubMed

48.

Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus D, Lubitz SA, Ellinor PT, Cheng S, Vasan RS, Lee DS, Wang TJ, Levy D, Benjamin EJ, Ho JE (2016) Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133(5):484–492. https://doi.org/10.1161/CIRCULATIONAHA.115.018614 PubMedPubMedCentral

49.

Barakat AF, Hussein AA, Saliba WI, Bassiouny M, Tarakji K, Kanj M, Jaber W, Rodriguez LL, Grimm R, Hussain MS, Russman A, Uchino K, Wisco D, Rasmussen P, Bain M, Vargo J, Zuccaro G, Gottesman D, Lindsay BD, Wazni OM (2016) Initial experience with high-risk patients excluded from clinical trials: safety of short-term anticoagulation after left atrial appendage closure device. Circ Arrhythm Electrophysiol 9(6):e004004. https://doi.org/10.1161/CIRCEP.116.004004 CrossRefPubMed

50.

Messori A, Trippoli S (2015) Left atrial appendage occlusion devices versus pharmacological agents for stroke prevention in atrial fibrillation. J Am Coll Cardiol 66(18):2056–2058. https://doi.org/10.1016/j.jacc.2015.07.080 CrossRefPubMed

51.

Amorosi SL, Armstrong S, da Deppo L, Garfield S, Stein K (2014) The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation. Europace 16(8):1131–1136. https://doi.org/10.1093/europace/euu038 CrossRefPubMed

52.

Reddy V, Akehurst R, Amorosi SL, Armstrong S, Beard S, Knight C, Taggart C, Holmes D (2015) Cost effectiveness of left atrial appendage closure versus warfarin for stroke risk reduction in non-valvular atrial fibrillation in CMS patients. Value Health 18(3):A44. https://doi.org/10.1016/j.jval.2015.03.260 CrossRef

53.

Reddy VY, Akehurst RL, Armstrong SO, Amorosi SL, Brereton N, Hertz DS, Holmes DR Jr (2016) Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. Europace 18(7):979–986. https://doi.org/10.1093/europace/euv412 CrossRefPubMedPubMedCentral

54.

Micieli A, Wijeysundera HC, Qiu F, Atzema CL, Singh SM (2016) A decision analysis of percutaneous left atrial appendage occlusion relative to novel and traditional oral anticoagulation for stroke prevention in patients with new-onset atrial fibrillation. Med Decis Mak 36(3):366–374. https://doi.org/10.1177/0272989X15593083 CrossRef

55.

Freeman JV, Hutton DW, Barnes GD, Zhu RP, Owens DK, Garber AM, Go AS, Hlatky MA, Heidenreich PA, Wang PJ, al-Ahmad A, Turakhia MP (2016) Cost-effectiveness of percutaneous closure of the left atrial appendage in atrial fibrillation based on results from PROTECT AF versus PREVAIL. Circ Arrhythm Electrophysiol 9(6):e003407. https://doi.org/10.1161/CIRCEP.115.003407 CrossRefPubMed

56.

Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, Huber K, Whisenant B, Kar S, Swarup V, Gordon N, Holmes D, PROTECT AF Steering Committee and Investigators (2014) Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 312(19):1988–1998. https://doi.org/10.1001/jama.2014.15192 CrossRefPubMed

Titel: Percutaneous left atrial appendage occlusion in the prevention of stroke in atrial fibrillation: a systematic review
verfasst von: Jayson R. Baman
Moussa Mansour
E. Kevin Heist
David T. Huang
Yitschak Biton
Publikationsdatum: 17.02.2018
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 2/2018
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-018-9681-4

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Imaging technologies for cardiac fiber and heart failure: a review

Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients—a systematic review and meta-analysis

Biomarkers in cancer therapy related cardiac dysfunction (CTRCD)

Protein tyrosine phosphatases in cardiac physiology and pathophysiology